Please login to the form below

Not currently logged in
Email:
Password:

Regeneron

This page shows the latest Regeneron news and features for those working in and with pharma, biotech and healthcare.

Lilly expands dermatology portfolio with $1.1bn Dermira deal

Lilly expands dermatology portfolio with $1.1bn Dermira deal

If approved, Lilly’s newly acquired drug will closely compete with Sanofi/Regenerons’s Dupixent (dupilumab) which grew 142% in the  last quarter to $637m.

Latest news

More from news
Approximately 61 fully matching, plus 152 partially matching documents found.

Latest Intelligence

  • Innovation and digital health comms recognised at Communiqué Awards Innovation and digital health comms recognised at Communiqué Awards

    Innovation in Healthcare Communications. One high profile winning campaign was Havas Lynx Group’s ‘See Below’ on behalf of Sanofi Genzyme and Regeneron.

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and

  • Regeneron and Bluebird sign $100m cell therapies deal Regeneron and Bluebird sign $100m cell therapies deal

    If Regeneron chooses not to opt-in, it will receive milestone payments and royalties from Bluebird on any potential resulting products. ... The deal involves Regeneron making a $100 million investment in Bluebird stock, at a premium of 59% over its

  • The good, the bad and the ugly The good, the bad and the ugly

    Ophthalmology. Ophthalmology is dominated by a small number of the same therapies marketed by different companies in different regions; Regeneron, Bayer and Santen all market Eylea, whereas Novartis and Roche market ... Regeneron remains the leading

  • Deal Watch October 2016 Deal Watch October 2016

    330. Ocular Therapeutics (US). Regeneron (US). Licence collaboration. Hydrogel sustained release aflibercept (Eylea) for wet macular degeneration.

More from intelligence
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Tiziana Life Sciences appoints clinical sciences VP Tiziana Life Sciences appoints clinical sciences VP

    Prior to this, Dr Evans held a number of scientific leadership positions while at Amgen, Johnson &Johnson and Regeneron.

  • Regeneron taps Pfizer for CFO Regeneron taps Pfizer for CFO

    Robert Landry succeeds Murray Goldberg. Former Pfizer senior VP Robert Landry has joined Regeneron as senior VP, finance, and will later take over as chief financial officer. ... We are extremely fortunate that Murray will stay at Regeneron through 2014

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...
White Paper for download - Explaining the price of your product
In this white paper, he breaks down the pricing options available to you, shares stories from his extensive experiences, and talks you through how to better define your pricing, step-by-step....
OPEN Health expands offering with the launch of a new Learning & Development specialist team
Enhanced expertise to deliver impactful internal training programmes for healthcare clients...

Infographics